C4 Therapeutics' oncology segment is dedicated to the discovery and development of targeted protein degradation therapies for various cancers. This involves extensive research and development activities focused on identifying and validating novel targets, designing and synthesizing degrader molecules, and conducting preclinical and clinical studies to evaluate the safety and efficacy of these therapies. The company utilizes its proprietary MonoDAC and BiDAC degrader platforms to develop orally bioavailable drugs that selectively degrade disease-causing proteins. Their lead product candidate, CFT7455, is currently in Phase 1/2 trials for multiple myeloma and non-Hodgkin lymphomas. Other pipeline programs include CFT8634 for synovial sarcoma and SMARCB1-deleted solid tumors, CFT1946 for V600X mutant BRAF cancers, and CFT8919 for EGFR L858R mutant NSCLC. These programs aim to address unmet medical needs in oncology by providing targeted treatments that can overcome drug resistance and improve patient outcomes. C4 Therapeutics collaborates with partners like Roche to accelerate the development and commercialization of its oncology therapies.

C4 Therapeutics' protein degradation platform is the foundation for its drug discovery and development efforts. This segment focuses on advancing the science of targeted protein degradation (TPD) through innovative technologies and methodologies. The company's proprietary MonoDAC and BiDAC degrader platforms enable the design of small molecule drugs that selectively degrade disease-causing proteins. Research and development activities in this area include optimizing degrader molecules for potency, selectivity, and bioavailability, as well as expanding the platform to target new protein classes and disease areas. C4 Therapeutics leverages its expertise in protein degradation to develop a pipeline of novel therapeutics for cancer, neurodegenerative diseases, and other disorders. The company's collaborations with partners like Biogen and Calico Life Sciences provide access to additional expertise and resources to further advance its protein degradation platform. This segment is critical to C4 Therapeutics' long-term growth and success, as it drives the discovery and development of innovative therapies that can address unmet medical needs.